Q (sonnet): list the portal studies for pediatric cancers that were published in the last 5 years

▶ list_studies
{
 "search": "pediatric",
 "limit": 100,
 "verbose": true
}

◀ result
{"result":[{"cancer_study_identifier":"all_phase2_target_2018_pub","name":"Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)","description":"Whole genome or whole exome sequencing on 298 Pediatric Acute Lymphoid Leukemia - Phase II samples. Comprehensive profiling of ALL Phase 2 samples. <p>TARGET data is intended exclusively for biomedical research using pediatric data (i.e., the research objectives cannot be accomplished using data from adults) that focus on the development of more effective treatments, diagnostic tests, or prognostic markers for childhood cancers. Moreover, TARGET data can be used for research relevant to the biology, causes, treatment and late complications of treatment of pediatric cancers, but is not intended for the sole purposes of methods and/or tool development (please see <a href=\"https://ocg.cancer.gov/programs/target/using-target-data\">Using TARGET Data</a> section of the OCG website). If you are interested in using TARGET data for publication or other research purposes, you must follow the <a href=\"https://ocg.cancer.gov/programs/target/target-publication-guidelines\">TARGET Publication Guidelines</a>.</p","type_of_cancer_id":"bll","sample_count":1978,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=all_phase2_target_2018_pub"},{"cancer_study_identifier":"nbl_target_2018_pub","name":"Pediatric Neuroblastoma (TARGET, 2018)","description":"Whole genome or whole exome sequencing on 1089 NBL samples. Comprehensive profiling of 1089 NBL samples. <p>TARGET data is intended exclusively for biomedical research using pediatric data (i.e., the research objectives cannot be accomplished using data from adults) that focus on the development of more effective treatments, diagnostic tests, or prognostic markers for childhood cancers. Moreover, TARGET data can be used for research relevant to the biology, causes, treatment and late complications of treatment of pediatric cancers, but is not intended for the sole purposes of methods and/or tool development (please see <a href=\"https://ocg.cancer.gov/programs/target/using-target-data\">Using TARGET Data</a> section of the OCG website). If you are interested in using TARGET data for publication or other research purposes, you must follow the <a href=\"https://ocg.cancer.gov/programs/target/target-publication-guidelines\">TARGET Publication Guidelines</a>.</p>","type_of_cancer_id":"nbl","sample_count":1089,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=nbl_target_2018_pub"},{"cancer_study_identifier":"aml_target_2018_pub","name":"Pediatric Acute Myeloid Leukemia (TARGET, 2018)","description":"Whole genome or whole exome sequencing on 333 TARGET-AML samples. Comprehensive profiling of TARGET-AML samples. <p>TARGET data is intended exclusively for biomedical research using pediatric data (i.e., the research objectives cannot be accomplished using data from adults) that focus on the development of more effective treatments, diagnost … (9828 more chars)

═ answer (success)
Filtering to studies published (per the name/year label) in the last 5 years — i.e., 2021–2026:

## Pediatric Cancer Studies Published 2021–2026

| Study | Cancer Type | Samples | Year |
|---|---|---|---|
| [Pediatric Acute Myeloid Leukemia (St. Jude, Nat Genet 2024)](https://www.cbioportal.org/study/summary?id=aml_stjude_2024) | AML | 887 | 2024 |
| [Pediatric European MAPPYACTS Trial (Gustave Roussy, Cancer Discov 2022)](https://www.cbioportal.org/study/summary?id=pancan_mappyacts_2022) | Mixed pediatric | 786 | 2022 |
| [Pediatric Neuroblastoma (MSK, Nat Genet 2023)](https://www.cbioportal.org/study/summary?id=nbl_msk_2023) | Neuroblastoma | 223 | 2023 |
| [Pediatric solid tumor PDXs (UTHSA, Nat Commun 2023)](https://www.cbioportal.org/study/summary?id=pancan_pdx_uthsa_2023) | Mixed solid tumors | 136 | 2023 |
| [Pediatric Pancan Tumors (MSK, Nat Commun 2022)](https://www.cbioportal.org/study/summary?id=mixed_kunga_msk_2022) | Mixed pediatric | 135 | 2022 |
| [Pediatric Tumors (MSK, 2025)](https://www.cbioportal.org/study/summary?id=pancan_ped_mai_msk_2025) | Mixed solid/CNS tumors | 60 | 2025 |
| [Pediatric Low-Grade Glioma (CTF, Acta Neuropathol 2021)](https://www.cbioportal.org/study/summary?id=lgg_ctf_synodos_2025) | Low-grade glioma (with NF1) | 31 | 2021* |
| [Pediatric Rhabdomyosarcomas (MSK, JCO Precis Oncol 2023)](https://www.cbioportal.org/study/summary?id=rms_msk_2023) | Rhabdomyosarcoma | 24 | 2023 |

*Note: the low-grade glioma study's identifier includes "2025" (data reprocessing date), but its citation is *Acta Neuropathol 2021* — I've listed it by the actual publication year.

Excluded from this list (published before 2021): TARGET ALL/NBL/AML/Wilms'/Rhabdoid studies (2018), DKFZ Pan-Cancer (2017), CPTAC Brain Cancer (2020), PPTC (2019), Ewing Sarcoma (2014), Columbia Pan-cancer (2016), and Medulloblastoma PCGP (2012).

This list is limited to studies whose name/description contains "pediatric" — some other cBioPortal studies (e.g., certain sarcoma or leukemia cohorts) may include pediatric patients without using that term. Let me know if you'd like me to broaden the search (e.g., by specific pediatric cancer types like medulloblastoma, Ewing sarcoma, or ALL) to catch any additional recent studies.

You can also browse and filter all pediatric studies interactively on the [cBioPortal study selector](https://www.cbioportal.org/study).